#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Conjunctivitis allergic Cystic fibrosis gastrointestinal disease Follicle centre lymphoma follicular grade I II – III refractory SAPHO syndrome Anaplastic large cell lymphoma T- and null-cell types Non-renal cell carcinoma of kidney Thymic carcinoma Neuronal ceroid lipofuscinosis Renal cancer metastatic Primary mediastinal large B-cell lymphoma Propionic acidaemia Heavy menstrual bleeding Hereditary angioedema Piriformis syndrome Polymyositis More trials…

    Learn about Rare Diseases

    Usher’s syndrome Pelizaeus-Merzbacher disease Rhabdomyosarcoma – Diagnostics Advanced systemic mastocytosis – Treatment Rosai-Dorfman syndrome Haemophilia A with anti factor VIII – Basic Information Haemophagocytic lymphohistiocytosis – Basic Information Hairy cell leukaemia – Life with Disease CADASIL – Treatment Glomerulonephritis membranoproliferative More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Gen1055 Argipressin Retinol Acetate Pivekimab Sunirine Metyrapone Bp Enoxaparin Sodium TEDUGLUTIDE Indacaterol Danazol CC-97540 Tinengotinib Clemastine Tiapride Venlafaxine Levodopa Tamoxifen Sparsentan Fluorouracil CAMOSTAT MESILATE Abelacimab More therapies…

    Learn about Your Condition

    Malignant neoplasm of choroid Breast cancer metastatic Melanoma recurrent Dry eye Neurotrophic keratopathy Pemphigoid Bronchostenosis Cutaneous lupus erythematosus Aortic disorder Small cell carcinoma Ectopic pregnancy Herpes simplex Mitral valve prolapse Pancreatic carcinoma Lung adenocarcinoma stage III More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Renal cell carcinoma

  • Study of Subcutaneous Nivolumab with or without Recombinant Human Hyaluronidase PH20 for Patients with Lung, Kidney, Melanoma, Liver, Colorectal, or Bladder Cancer

    Not recruiting

    1 1 1 1
    Investigated Drugs:
    • Nivolumab
    France Italy The Netherlands Poland Spain

  • Study of Pembrolizumab and Lenvatinib for Patients with Advanced Non-Clear Cell Kidney Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Renal cell carcinoma
    Investigated Drugs:
    • Lenvatinib
    • Pembrolizumab
    France Hungary Italy Poland Spain

  • Study of Pembrolizumab, Belzutifan, and Lenvatinib for Patients with Advanced Clear Cell Renal Cell Carcinoma

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Quavonlimab
    • Belzutifan
    • Lenvatinib
    Croatia Czechia Denmark Finland France Germany +8

  • Study Comparing Tivozanib and Nivolumab Combination to Tivozanib Alone in Patients with Renal Cell Carcinoma After Previous Immune Therapy

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Renal cell carcinoma
    Investigated Drugs:
    • Tivozanib
    • Nivolumab
    Belgium Czechia France Germany Italy Poland +2

  • Study of Pembrolizumab, Lenvatinib, and Belzutifan for Patients with Renal Cell Carcinoma

    Not recruiting

    1 1 1 1
    Investigated Drugs:
    • Favezelimab
    • Mk-4830
    • Quavonlimab
    France Hungary The Netherlands Poland Spain
Previous Page
1 … 5 6 7

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!